Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AUTL
AUTOLUS THERAPEUTICS PLC
NASDAQ
$2.34
▼ DOWN 0.85% (-0.02)

KEY STATISTICS

Market Cap$622.78 M
52w High$2.58
52w Low$1.18
Dividend Yield—
Frequency—
P/E-2.15
Volume1.44M
Shares Out.266.14M

COMPANY

LEADERSHIP

Christian Martin Itin
CHIEF EXECUTIVE
Christian Martin Itin

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 22, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
752

PRICE TARGET

Target High$11.00
Target Low$7.60
Target Median$8.00
Target Consensus$8.87

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$39.96M
NOV
11
WED

PRICE

$2.34 ▼ DOWN 0.85% (−$0.02)
$2.30$2.33$2.359:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.34

About Autolus Therapeutics plc

https://www.autolus.com ↗

Autolus Therapeutics plc is a London-based clinical-stage biopharmaceutical company developing T cell therapies for cancer, including programs for leukemia, lymphoma, neuroblastoma, and multiple myeloma.

INDUSTRY

Biotechnology

A PRODUCT AUTOLUS THERAPEUTICS PLC IS KNOWN FOR

AUCATZYL® (obecabtagene autoleucel; obe-cel)
AUCATZYL® (obecabtagene autoleucel; obe-cel)

AUCATZYL® is Autolus' flagship personalized CAR T-cell therapy for relapsed/refractory B-cell ALL, marking the company's first commercial product and its key offering in the US, UK, and EU markets.

COMPETITORS

COMPETITOR
ALLO COMPARE
BMY COMPARE
GILD COMPARE
IOVA COMPARE
NVS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$21.14M $23.27M ▲— $45.67M ▲
Reportable Segment— — $26.22M —
License$50K $1.02M ▲— $17K ▼

Revenue by Geography

MapREGIONQ1-2025Q2-2025Q3-2025Q4-2025
Europe— — $50K $0 ▼
UNITED STATES$8.98M $20.92M ▲— $0 ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
7
RANKED BY POSITION SIZE
IBB
0.03% · 1.5M
CANC
0.30% · 268.1K
MOON
2.00% · 90.8K
GWX
0.02% · 85.7K
QQQS
0.61% · 59.8K
APIE
0.01% · 31.6K
BIB
0.02% · 7.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
50.45%
HOLDERS
125
TOP 12 OF 125 · RANKED BY POSITION SIZE
Mak Capital One LLC
33.6M sh · $46.4M
Blackstone Inc.
20.5M sh · $28.27M
Armistice Capital, LLC
17.5M sh · $34.83M
Syncona Portfolio Ltd
16.6M sh · $33.12M
Tfg Asset Management Gp Ltd
9.5M sh · $13.11M
Schroder Investment Management Group
9.5M sh · $12.05M
Citadel Advisors LLC
6.0M sh · $9.85M
Renaissance Technologies LLC
4.9M sh · $7.96M
Frazier Life Sciences Management, L.P.
4.6M sh · $9.2M
Blackrock Inc.
4.4M sh · $15.44M
Blackrock, Inc.
3.7M sh · $7.33M
Bnp Paribas Asset Management Holding S.A.
3.4M sh · $4.64M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
YOUNG WILLIAM D
Purchase · 47.5K shares
2026-06-29
★
DIRECTOR
Rao Madduri Ravin
Purchase · 31.7K shares
2026-06-29
★
DIRECTOR
Rao Madduri Ravin
Purchase · 47.5K shares
2026-06-29
★
DIRECTOR
Richardson Ryan
Purchase · 31.7K shares
2026-06-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Needham BUY Mizuho OUTPERFORM

SECTORS PEERS

PEERPRICE
LBRX$47.73COMPARE
SLDB$9.77COMPARE
ANNX$4.97COMPARE
AURA$7.40COMPARE
BNTC$12.47COMPARE
RCKT$3.86COMPARE
NMRA$1.39COMPARE
QSI$0.78COMPARE